Lantern Pharma Progresses Novel ADC Initiative in Various Solid Cancer Types

Lantern Pharma is advancing a new ADC program aimed at various solid tumor cancers. The program which uses a cryptophycin-based ADC has already shown very high potency in preclinical tests. The company employs its RADR® AI platform for drug development, focusing on target selection and payload characterization, with the strategy set to speed up their pipeline development, reducing time and cost for advancing drug programs to clinical trials.

The following article originally appeared in MarketScreener.

Lantern Pharma Advances unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers. Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and preclinical proof-of-concept of a novel, highly potent, cryptophycin-based ADC. The cryptophycin ADC has shown picomolar potency in a wide range of solid tumors tested in preclinical development and is being further evaluated for clinical potential in six solid tumor indications.

The company has leveraged RADR®?, a proprietary AI platform for oncology drug development, for target selection and molecular payload characterization in ADCs, and a unique, controlled conjugation approach for maximizing drug-to-antibody ratios while controlling for non-specific conjugation. The proprietary AI and machine learning (ML) RADR®? platform leverages over 60 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development.

By harnessing the power of AI and with input from world-class scientific advisors and collaborators, have accelerated the development of company growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, company newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in approximately 2-3 years and at approximately $1.0-2.0 million per program.

For more, please find the original story source here.